ClinicalTrials.gg
Not yet recruitingNCT07860359Updated Oct 21, 2026

Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers

An interventional study of Image-Based Counseling and Smoking Cessation Coaching in Lung Cancer (Diagnosis), Smoking Cessation and Lung Neoplasm, sponsored by Hôpital Fribourgeois. Not yet recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Hôpital Fribourgeois · Not applicable, Interventional, and Prevention

How we know

Updated Oct 7, 2026Eligibility revisedInterventions changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
50 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Lung Neoplasms with a site in Switzerland — 26 open to participants now, 32 under way, 11 of them phase 3. Lung Neoplasms · Switzerland.

Planned enrollment
41st of 77
116 · median 136
Started
2027
the only one that year
No phase
13 of 98
6 open now
Primary completion
2031-06
later than 29 of 31 live
Registered
98th of 98
by date

Among the 98 studies in Lung Neoplasms with a site in Switzerland, this one is the 41st largest by planned enrollment of the 77 interventional ones that give a count, is the only one that started in 2027, is one of 13 with no phase, reaches primary completion later than 29 of the 31 other live ones, and was the 98th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

26 of the 98 studies in Lung Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lung Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

Lung cancer is common and serious, but when detected early, the chances of recovery are significantly better. Tobacco use is the leading cause. To help people break free from smoking, the Fribourg Cantonal Hospital (HFR), the Center for Tobacco Prevention (CIPRET), and the Fribourg Cancer League are joining forces in the STOP-LungCancer study (Smoking Termination Outcomes with Pulmonary Low Dose Computed Tomography for Lung Cancer Screening).

What is the goal of this study? The investigators want to determine whether seeing and understanding images of the participants' own lungs helps participants quit smoking for good. Smoking cessation will be verified at 6 months using a breath test (measuring carbon monoxide), followed by a 2-year follow-up.

How does participation work? The study is open to 116 residents of the canton of Fribourg aged 50 to 79 who are heavy smokers and motivated to quit.

The program includes:

  1. Personalized support: 4 smoking cessation coaching sessions organized by CIPRET.
  2. Lung computed tomography (CT) scans: 3 exams spaced one year apart. This scan involves no needles or injections. The radiation dose is very low, about 0.6 millisieverts (mSv) per scan, and the associated risk is considered very low.
  3. A review of the images with a doctor: During dedicated consultations, a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain the condition of the lungs and heart.

What are the benefits? Participants receive both tailored support to quit smoking and close monitoring to detect any potential issues at a very early stage.

03

Conditions studied

  • Lung Cancer (Diagnosis)
  • Smoking Cessation
  • Lung Neoplasm

Keywords

  • lung cancer
  • screening
  • smoking
  • tobacco
  • cessation
  • termination
  • counselling
  • coaching
  • low dose
  • low-dose
  • chest
  • CT
  • scan
  • cigarette
  • LDCT
  • LCS
  • early detection
  • behavioral intervention
  • cancer
  • primary prevention
  • exhaled carbon monoxide
  • nicotine
  • lung neoplasms
  • lung neoplasm
  • computed tomography
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
50 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residence in the canton of Fribourg
  • Willingness to quit smoking
  • Current smoker: > or = 20 packs years

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of cancer
  • Major medical problems (, ECOG ≥ 2)
  • Chest computed tomography (CT) scan in the last 12 months
  • Hemoptysis or unintentional weight loss > 7 kilograms (kg) in the last year
  • Pregnancy
  • Refusal to be informed of incidental findings of medical importance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Combined Low-Dose Computed Tomography Screening and Smoking Cessation Coaching

    Single-arm experimental cohort of heavy smokers undergoing an integrated lung cancer screening and smoking cessation pathway. All enrolled participants receive the combined intervention strategy, which pairs personalized chest computed tomography (CT) imaging results with dedicated specialist counseling and structured behavioral smoking cessation support. This arm aims to evaluate how visual radiological feedback combined with tobacco cessation counseling impacts long-term smoking abstinence rates.

    Behavioral: Image-Based Counseling · Behavioral: Smoking Cessation Coaching · Radiation: Low-Dose Chest Computed Tomography (LDCT)

Interventions

  • BehavioralImage-Based Counseling

    Face-to-face physician consultations where a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain lung and cardiovascular health, creating a visual "teachable moment".

  • BehavioralSmoking Cessation Coaching

    Four structured behavioral counseling sessions delivered by certified tobacco cessation experts of the Center for Tobacco Prevention (CIPRET), personalized to support long-term abstinence.

    Also known as: Smoking Cessation Counselling

  • RadiationLow-Dose Chest Computed Tomography (LDCT)

    Low-dose chest computed tomography (LDCT) scans without intravenous contrast at baseline, 12 months, and 24 months, and additional follow-up LDCT when indicated by the screening result (Lung Computed Tomography Screening Reporting and Data System \[Lung-RADS\] category 3).

    Also known as: lung cancer screening (LCS)

06

What researchers measure

Primary outcomes

  1. 6-Month Smoking Abstinence Rate

    Proportion of participants who achieve smoking abstinence at 6 months after the first chest computed tomography (CT). Abstinence is self-reported and objectively validated using exhaled carbon monoxide (CO) measurement.

    Time frame: 6 months after the first chest computed tomography (CT)

Secondary outcomes

  1. Smoking Abstinence Rate at 12 Months

    Proportion of participants reporting smoking abstinence at the 12-month visit, confirmed by exhaled carbon monoxide (CO) measurement.

    Time frame: 12 months after the first chest computed tomography

  2. Smoking Abstinence Rate at 24 Months

    Proportion of participants reporting smoking abstinence at the 24-month visit, confirmed by exhaled carbon monoxide (CO) measurement.

    Time frame: 24 months after the first chest computed tomography

  3. Detection Rate of Lung Nodules and Lung Cancer

    Proportion of participants with positive low-dose computed tomography (LDCT) findings requiring further diagnostic follow-up or tissue biopsy, categorized according to the standardized Lung Computed Tomography Screening Reporting and Data System (Lung-RADS) assessment categories.

    Time frame: Baseline, 12 months, and 24 months

  4. Prevalence of Relevant Incidental Findings on Chest Computed Tomography

    Proportion of relevant non-lung-nodule incidental findings detected on low-dose chest computed tomography, such as smoking-related lung disease, cardiac abnormalities and other findings unrelated to smoking.

    Time frame: Baseline, 12 months, and 24 months

  5. Factors Potentially Influencing Smoking Cessation Success

    Exploratory analysis evaluating demographics such as age, sex, place of residence, socioeconomical class, and other factors such as smoking-related lung disease, and cardiac abnormalities. These analyses are exploratory in nature and are intended to generate hypotheses for future studies. No definitive causal inference will be drawn from these analyses.

    Time frame: At baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available to protect participant privacy and maintain confidentiality in accordance with Swiss regulatory requirements (Human Research Act and Federal Act on Data Protection). Aggregated data and primary results will be available in peer-reviewed scientific publications.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 53 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jun 30, 2031
CompletionEst.
Dec 31, 2032
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fribourg Cantonal Hospital (HFR) · Fribourg, Switzerland
Show 1 removed
  • HFR Fribourg · Fribourg, Switzerland
Oct 7, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedChest computed tomography (CT) scan in the last 12 months
  • EditedHemoptysis or unintentional weight loss > 7 kilograms (kg) in the last year
Oct 7, 2026
Interventions
Added Radiation: Low-Dose Chest Computed Tomography (LDCT); removed Radiation: low dose chest CT. Arm changed Combined LDCT Screening and Smoking Cessation Coaching→Combined Low-Dose Computed Tomography Screening and Smoking Cessation Coaching
Oct 7, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedPrevalence of Relevant Incidental CT FindingsFindings on Chest Computed TomographyTime frame: Baseline, 12 months, and 24 months
  • DescriptionDetection Rate of Lung Nodules and Lung Cancer: how it is measured was reworded
Oct 7, 2026
Title
STOP-LungCancer: Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Oct 7, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 3 updates
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: responsible party
  2. Oct 7, 2026
    1 site added, 1 site removed
    Show site
    • Fribourg Cantonal Hospital (HFR) · Fribourg, Switzerland
    Show 1 removed
    • HFR Fribourg · Fribourg, Switzerland
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedChest computed tomography (CT) scan in the last 12 months
    • EditedHemoptysis or unintentional weight loss > 7 kilograms (kg) in the last year
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedPrevalence of Relevant Incidental CT FindingsFindings on Chest Computed TomographyTime frame: Baseline, 12 months, and 24 months
    • DescriptionDetection Rate of Lung Nodules and Lung Cancer: how it is measured was reworded
    Interventions Added Radiation: Low-Dose Chest Computed Tomography (LDCT); removed Radiation: low dose chest CT. Arm changed Combined LDCT Screening and Smoking Cessation Coaching→Combined Low-Dose Computed Tomography Screening and Smoking Cessation Coaching
    Title STOP-LungCancer: Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
    + 3 other changes: verification date, description and contact details
  3. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860359
Lead sponsor
Hôpital Fribourgeois
Collaborators
CIPRET Fribourg (Centre d'information pour la prévention du tabagisme)
Responsible party
Philippe Khafagy (Senior Attending Physician, Hôpital Fribourgeois) — Principal investigator
First posted
Oct 6, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 30, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 21, 2026

Study contacts

Sandrine Foucras
Contact
Sandrine.Foucras@h-fr.ch
+41 26 306 21 06
Philippe Khafagy, MD
principal investigator · Hôpital Fribourgeois
Jon Lutz, MD
principal investigator · Hôpital Fribourgeois

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion